Compare Stocks → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNASDAQ:CTICNASDAQ:DYNNASDAQ:PHAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$10.18+14.5%$9.90$2.09▼$14.84$546.97M0.086.07 million shs8.49 million shsCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/ADYNDyne Therapeutics$28.39-0.4%$24.01$6.40▼$30.27$2.33B0.952.30 million shs1.32 million shsPHARPharming Group$10.84$11.56$9.70▼$16.71$727.47M0.172,870 shs476 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+2.77%-4.82%-21.47%-23.49%+101.13%CTICCTI BioPharma0.00%0.00%0.00%0.00%+108.01%DYNDyne Therapeutics+6.42%+2.11%+18.55%+116.57%+156.06%PHARPharming Group+0.09%-1.45%-3.90%-4.75%-14.65%“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.315 of 5 stars3.42.00.00.02.11.70.0CTICCTI BioPharma0.0714 of 5 stars1.10.00.00.00.61.70.6DYNDyne Therapeutics4.0157 of 5 stars4.62.00.00.02.55.00.6PHARPharming Group2.6859 of 5 stars3.55.00.00.03.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.75Moderate Buy$15.7554.72% UpsideCTICCTI BioPharma2.17Hold$8.50-6.49% DownsideDYNDyne Therapeutics3.14Buy$37.4331.84% UpsidePHARPharming Group3.00Buy$37.00241.33% UpsideCurrent Analyst RatingsLatest CTIC, ALT, PHAR, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/26/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.003/8/2024DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $31.003/6/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.003/6/2024DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $41.003/6/2024DYNDyne TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $29.003/5/2024DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$44.00 ➝ $47.002/20/2024DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$4.41M124.03N/AN/A$3.77 per share2.70CTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/APHARPharming Group$245.32M2.97$0.10 per share111.32$3.27 per share3.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$84.71M-$1.54N/AN/AN/AN/A-46.81%-42.23%5/9/2024 (Estimated)CTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/ADYNDyne Therapeutics-$235.94M-$3.94N/AN/AN/AN/A-136.35%-103.67%5/9/2024 (Estimated)PHARPharming Group-$10.12M-$0.14N/AN/AN/A-4.13%-4.53%-2.15%5/9/2024 (Estimated)Latest CTIC, ALT, PHAR, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 million3/5/202412/31/2023DYNDyne Therapeutics-$0.92-$1.09-$0.17-$1.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACTICCTI BioPharmaN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A12.8912.89CTICCTI BioPharmaN/A1.271.26DYNDyne TherapeuticsN/A2.532.53PHARPharming Group0.624.163.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CTICCTI BioPharma91.45%DYNDyne Therapeutics96.68%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%CTICCTI BioPharma7.61%DYNDyne Therapeutics32.89%PHARPharming Group2.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5253.73 million51.53 millionOptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableDYNDyne Therapeutics14181.96 million55.00 millionOptionablePHARPharming Group33267.11 million65.72 millionNot OptionableCTIC, ALT, PHAR, and DYN HeadlinesSourceHeadlinePharming Group (NASDAQ:PHAR) Shares Gap Up to $11.00americanbankingnews.com - March 24 at 6:22 AMPharming Group (NASDAQ:PHAR) Stock Price Down 5%marketbeat.com - March 19 at 4:49 PMPharming Group (NASDAQ:PHAR) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 18 at 5:10 PMPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volumemarketbeat.com - March 18 at 11:25 AMUber to pay $178 million in Australia taxi class action settlementmsn.com - March 18 at 3:45 AMPharming Group (NASDAQ:PHAR) Expected to Post Q1 2024 Earnings of $0.01 Per Shareamericanbankingnews.com - March 18 at 1:28 AMPharming reports Q4 resultsmsn.com - March 15 at 7:46 PMPharming Group N.V. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - March 14 at 9:06 AMPharming Group (NASDAQ:PHAR) Stock Price Down 6.5%marketbeat.com - March 13 at 3:39 PMPharming Group (NASDAQ:PHAR) Short Interest Up 900.0% in Februarymarketbeat.com - March 12 at 11:13 PMPharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14finanznachrichten.de - February 29 at 6:26 AMPharming Group N.V. (PHGN.F)finance.yahoo.com - February 20 at 3:10 PMPharming Group N.V.: Pharming Group to participate in February investor conferencesfinanznachrichten.de - February 8 at 3:55 AMPharming Group to participate in February investor conferencesfinance.yahoo.com - February 8 at 3:55 AMAstria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readoutseekingalpha.com - February 5 at 12:52 AMPharming Group: Strong Buy Rating on Robust Revenue Growth and Promising Clinical Pipeline Expansionmarkets.businessinsider.com - January 8 at 7:31 PMWhat's Going On With Netherlands-Based Biopharma Company Pharming Shares Today?msn.com - January 8 at 2:30 PMPharming Group issues full-year 2023 guidanceseekingalpha.com - January 8 at 5:14 AMPharming Stock (NASDAQ:PHAR) Dividends: History, Yield and Datesbenzinga.com - January 6 at 9:56 AMChief Information Security Officertweakers.net - January 1 at 7:34 AMBuy Rating Affirmed for Pharming Group Amid Promising Clinical Advances and FDA Feedbackmarkets.businessinsider.com - December 15 at 12:50 AMPharming To Develop Leniolisib For Additional PIDs Beyond APDS; Phase 2 Trial To Initiate In Q2markets.businessinsider.com - December 13 at 8:30 AMAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Pharming Group (PHAR)markets.businessinsider.com - December 13 at 1:33 AMPharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)finance.yahoo.com - December 13 at 1:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityIs UnitedHealth Group Stock a Strong Buy or a Falling Knife?March 5, 2024 7:08 AMView Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?The Ozempic Diet Trend is Lifting These 2 Carnivore StocksMarch 4, 2024 6:28 AMView The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks3 Hot Stocks Bought by Members of Congress: Follow the MoneyMarch 1, 2024 7:05 AMView 3 Hot Stocks Bought by Members of Congress: Follow the MoneyAll Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.CTI BioPharmaNASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Dyne TherapeuticsNASDAQ:DYNDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.